Anthropic chokes AI devs as Claude Code's SaaS war escalates

Enterprise (1)

• Claude Code revenue grew from $1 billion to $2.5 billion annualized in two months. Anthropic's enterprise share reached 70% of first-time buyers, and its overall revenue run rate hit $19 billion.

Models (1)

• The quarter saw rapid frontier model releases: GPT-5.2 Codex, Genie 3, Opus 4.6, GPT-5.3 Codex, Sonnet 4.6, Gemini 3.1 Pro, Nano Banana 2, and GPT-5.4, with no single benchmark winner across common tests.

Open Source (1)

• OpenClaw became the most starred open-source project on GitHub. Nvidia launched Nemo Claw as an enterprise-grade wrapper, and Anthropic integrated its features into Claude Code and Claude Co-work.

AI & Tech (5)

• Survey data shows 71% of practitioners used vibe coding, 62% used agentic automation, and the average respondent uses 3.5 models. ROI shifted from time savings (13.6% of use cases) to increased output and new capabilities.
• Customer service AI adoption is mature with 91% of businesses experimenting, but 64% of customers prefer no AI in interactions. Legal AI adoption lags, with only 15% of tasks using AI despite 80% capability.
• HR AI deployment grew 320% in 12 months, from 19% to 61%. Finance AI adoption faces data quality obstacles, with 91% of firms reporting low impact.
• Generative Engine Optimization (GEO) market was under $1 billion in 2025, projected to reach $34 billion by 2034. Sales AI use cases are mature, with 63% categorized as 'primetime' for most organizations.
• Nathaniel Whittemore argues the capability overhang - the gap between AI's potential and deployed value - is widening, increasing the disparity between leading and lagging companies.

AI & Tech (4)

• Whittemore argues Q1 2026 marked AI's second moment, shifting from viable chatbots to workable agentic systems with higher economic and corporate stakes.
• Industry AI capex is projected to reach $650 billion in 2026, triple the spending from a couple of years ago and exceeding the inflation-adjusted cost of the US interstate highway buildout.
• The Generative Engine Optimization market was valued under $1 billion in 2025 but is projected to reach nearly $34 billion by 2034 as AI referrals convert better than traditional search.
• Whittemore notes a widening capability overhang where the gap between potential AI value and actual deployed value increases costs, creating a larger divide between leading and lagging companies.

AI Infrastructure (1)

• Gartner predicts 40% of enterprises will have working agents in production by end of 2026, fueled by products like agent credit cards from Ramp and Stripe.

Enterprise (2)

• Survey data indicates a shift from efficiency AI to opportunity AI, with time-saving use cases dropping from 19.9% to 13.6% of ROI between January and February 2026.
• HR AI deployment grew 320% in 12 months from 19% to 61% adoption, while seven states have enacted AI employment regulations.

Biology (5)

• Longevity science focuses on cellular rejuvenation - the idea that aged cells can be made to function like younger cells. Susan Domonius points to embryos as proof, noting they shed inherited aging markers shortly after fertilization.
• Shinya Yamanaka won the Nobel Prize in 2006 for reverting aged mouse skin cells to embryonic form using powerful genes. Early attempts to apply these Yamanaka factors to mice caused monstrous tumors, as cells became unspecialized and developed fatal teratomas.
• Juan Carlos Izpisua Belmonte tweaked the Yamanaka formula, applying a reduced dose to fast-aging mice. The mice lived longer, looked younger with less gray fur, had stronger muscles, healed faster, and became friscier - lab technicians thought they were replaced.
• David Sinclair, a Harvard genetics professor, is a controversial figure in longevity research. Domonius notes colleagues criticize him for overselling promises, circulating unsupported claims about reversing aging in dogs, and co-founding a wellness platform with non-mainstream practices.
• Sinclair’s key breakthrough involved dropping the most cancer-prone Yamanaka factor and using only three to restore vision in blinded mice without causing cancer. Life Biosciences, his biotech, has FDA approval for human safety trials targeting glaucoma and nystagmus.

Longevity (4)

• Altos Labs recruited top scientists like Belmonte by offering million-dollar salaries, triggering a major academic migration to private industry. The company focuses on predictive research using human organoids and AI-driven virtual cells to bypass unreliable mouse models.
• Hal Barron, Altos Labs CEO, distances the company from extreme longevity promises like living to 150. Domonius says Barron aims for reasonable goals, such as extending human health by a few years or preserving ovary function, which he considers revolutionary.
• Extending lifespan raises economic and philosophical issues. Social Security isn't designed for people living to 110. Domonius says if people are healthier longer, they might remain active and fill roles amid population decline, reducing pressure on young caregivers.
• Hal Barron stated we already know how to reverse aging through diet, exercise, sleep, and sociability. Domonius points to GLP-1 drugs as evidence that behavioral solutions are insufficient, arguing accessible medical interventions could transform health for those in food deserts or under stress.

Health (1)

• The realistic expectation for cellular rejuvenation is treating specific diseases like glaucoma within a decade, not dramatically expanding lifespan. Domonius argues the goal is curing disease to reduce suffering and extend healthy years, not achieve radical longevity.

AI & Tech (3)

• Anthropic is aggressively banning third-party tools like T3 Code and OpenClaw that interface with Claude Code. Theo attributes this to a compute crisis and poor caching implementations that increase costs.
• Theo's primary conspiracy is that Anthropic now forces all Claude Code users onto the dumber 1M-context model version to route traffic away from scarce Nvidia GPUs and onto partners like AWS and Google TPUs, explaining the performance drop.
• Theo attributes Anthropic's problems to a research-first, safety-obsessed culture that devalues engineering and product reliability, creating opaque policies and a 'holier-than-thou' attitude that frustrates developers.